Mildronate, a novel fatty acid oxidation inhibitor and antianginal agent, reduces myocardial infarct size without affecting hemodynamics

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 3, 2006, Pages 493-499

  Sesti, Casilde ^a   Simkhovich, Boris Z ^a,b   Kalvinsh, Ivars ^c   Kloner, Robert A ^a,b  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c LATVIAN INSTITUTE OF ORGANIC SYNTHESIS   (Latvia)

Author keywords

Fatty acid oxidation; Infarct size; Myocardial infarction

Indexed keywords

ANTIANGINA PECTORIS AGENT; BLOCKING AGENT; FATTY ACID; MILDRONATE; 3 (2,2,2 TRIMETHYLHYDRAZINE)PROPIONATE; 3-(2,2,2-TRIMETHYLHYDRAZINE)PROPIONATE; CARDIOVASCULAR AGENT; METHYLHYDRAZINE DERIVATIVE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CORONARY HEMODYNAMICS; CORONARY RISK; DRUG EFFECT; FATTY ACID OXIDATION; FEMALE; FREQUENCY ANALYSIS; HEART ARRHYTHMIA; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART RATE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; ANGINA PECTORIS; ANIMAL; BLOOD PRESSURE; BODY WEIGHT; HEART INFARCTION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANGINA PECTORIS; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR AGENTS; FATTY ACIDS; FEMALE; HEART RATE; METHYLHYDRAZINES; MYOCARDIAL INFARCTION; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33745713606     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000211732.76668.d2     Document Type: Article

References (40)

1. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99:578-588.
2. Grynberg A. Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents. Curr Pharm Des. 2005;11:489-509.
3. Braunwald E, Maroko PR. The reduction of infarct size - an idea whose time (for testing) has come. Circulation. 1974;50:206-209.
4. Simkhovich BZ, Shutenko ZV, Meirena DV, et al. 3-(2,2,2- trimethylhydrazinium) proprionate (THP): a novel g-butyrobetaine hydroxylase inhibitor with cardioprotective properties. Biochem Pharmacol. 1988;37:195-202.
5. Kirimoto T, Nobori K, Asaka N, et al. Beneficial effect of MET-88, a γ-butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dogs. Arch Int Pharmacodyn Ther. 1996;331:163-178.
6. Dhar PK, Grupp IL, Schwartz A, et al. Reduction of carnitine content by inhibition of its biosynthesis results in protection of isolated guinea pig hearts against hypoxic damage. J Cardiovasc Pharmacol Ther. 1996;1:235-242.
7. Aoyagi T, Sugiura S, Eto Y, et al. Inhibition of carnitine synthesis protects against left ventricular dysfunction in rats with myocardial ischemia. J Cardiovasc Pharmacol. 1997;30:468-474.
8. Asaka N, Muranaka Y, Kirimoto T, et al. Cardioprotective profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts. Fundam Clin Pharmacol. 1998;12:158-163.
9. Hayashi Y, Tajima K, Kirimoto T, et al. Cardioprotective effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor, on cardiac dysfunction induced by ischemia/reperfusion in isolated rat hearts. Pharmacology. 2000;61:238-243.
10. Dambrova M, Liepinsh E, Kalvinsh I. Mildronate: cardioprotective action through carnitine-lowering effect. Trends Cardiovasc Med. 2002;12:275-279.
11. American Heart Association. Position of the American Heart Association on research animal use. Circulation. 1985;71:849A-850A.
12. Degrace P, Demizieux L, Cresti J, et al. Fatty acid oxidation and related gene expression in heart depleted of carnitine by mildronate treatment in the rat. Mol Cell Biochem. 2004;258:171-182.
13. Hayashi Y, Kirimoto T, Asaka N, et al. Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction. Eur J Pharmacol. 2000;395:217-224.
14. van der Horst IC, Zijlstra F, van't Hof AW, et al. Glucose insulin potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. The glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol. 2003;42:784-791.
15. Faxon DP, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol. 2002;40:1199-1204.
16. Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction. Circulation. 2001;104:2778-2783.
17. Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the complement inhibition in myocardial infarction treated with thrombolytics (COMPLY) trial. Circulation. 2003;108:1176-1183.
18. Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation. 2003;108:1184-1190.
19. Zeymer U, Suryapranata H, Monassier JP, et al. The Na+/H+ exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the Evaluation of the Safety and Cardioprotective effects of eniporide in Acute Myocardial Infarction (ESCAMI) Trial. J Am Coll Cardiol. 2001;38:1644-1650.
20. Steg G, Grollier G, Gallay P, et al. A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol. 2001;77:263-273.
21. Tavackoli S, Ashitkov T, Hu ZY, et al. Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels. Coronary Artery Dis. 2004;15:53-58.
22. Birnbaum Y, Ye Y, Rosanio S, et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res. 2005;65:345-355.
23. Cholesterol Treatment Trialists (CTT) Collaborators. Efficasy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomized trials of statins. Lancet. 2005;366:1267-1278.
24. Corr PB, Gross RW, Sobel BE. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ Res. 1984;55:135-154.
25. Yamada KA, McHowat J, Yan G-X, et al. Cellular uncoupling induced by accumulation of long-chain acylcarnitine during ischemia. Circ Res. 1994;74:83-95.
26. 2+ efflux from the sarcoplasmic reticulum. J Cardiovasc Pharmacol. 2000;36:14-21.
27. DaTorre SD, Creer MH, Pogwizd SM, et al. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol. 1991;23(Suppl 1):11-22.
28. Shug AL, Shrago E, Bittar N, et al. Acyl-CoA inhibition of adenine nucleotide translocation in ischemic myocardium. Am J Physiol. 1975;228:689-692.
29. Piper HM, Das A. Detrimental actions of endogenous fatty acids and their derivatives. A study of ischaemic mitochondrial injury. Basic Res Cardiol. 1987;82(Suppl 1):187-196.
30. Kobayashi A, Fujisawa S. Effect of L-carnitine on mitochondrial acyl-CoA esters in the ischemic dog heart. J Mol Cell Cardiol. 1993;26:499-508.
31. Asaka N, Muranaka Y, Kirimoto T, et al. Cardioprotectrive profile of MET-88, an inhibitor of carnitine synthesis, and insulin during hypoxia in isolated perfused rat hearts. Fundam Clin Pharmacol. 1998;12:158-163.
32. Kuwajima M, Harashima H, Hayashi M, et al. Pharmacokinetic analysis of the cardioprotective effect of 3-(2,2,2-trimethylhydrazinium) propionate in mice: inhibition of carnitine transport in kidney. J Pharmacol Exp Ther. 1999;289:93-102.
33. 2+-ATPase and hexokinase type I in rat hearts with myocardial infarction. Basic Res Cardiol. 2000;95:343-348.
34. Kagan TI, Simkhovich BZ, Priedena IA, et al. Evaluation of functional state of mitochondria in rat heart with respect to the course of mildronate treatment. Laboratornye Zhyvotnye. 1993;III:29-32. (Russian).
35. Karpov RS, Dudko VA, Shipulin VM, et al. The clinical instrumental evaluation of treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries. Ter Arkh. 1991;63:90-93. (Russian).
36. Skarda I, Klincare D, Dzerve V, et al.Modulation of myocardial energy metabolism with mildronate - An effective approach in the treatment of chronic heart failure. Proc Latvian Acad Sci. 2001;55:73-79.
37. Chumburidze V, Kikalishvili T, Sulashvili T. Definition of the therapeutic effect of mildronate in patients with chronic heart failure. Georgian Med News. 2005;5:25-29. (Russian).
38. Ianson TM, Bauman VR, Grom NP, et al. Cardioprotective effect of carnitine and its synthetic analog 3-(2,2,2-trimethylhydrazinium) proprionate in rats with experimental myocardial infarction. Vopr Med Khim. 1988;34:122-125. (Russian).
39. Ratunova TM, Bauman VR, Kalvinsh IIa. The cardioprotective action of carnitine and its structural analoque 3-(2,2,2-trimethylhydrazine) propionate on cardiac energy metabolism in experimental occlusion of the coronary artery in rats. Farmakol Toksikolo. 1989;52:24-27. (Russian).
40. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-1172.